UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh, KM; Burgel, PR; Franssen, FM; Lopez-Campos, JL; Loukides, S; Hurst, JR; Fležar, M; ... Wedzicha, JA; + view all (2017) How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? American Journal of Respiratory and Critical Care Medicine , 196 (2) pp. 139-149. 10.1164/rccm.201609-1794CI. Green open access

[img]
Preview
Text
LABA_LAMA_AJRCCM.pdf - ["content_typename_Accepted version" not defined]

Download (1MB) | Preview

Abstract

Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease (COPD). Several studies have documented that long-acting bronchodilators (LABDs) can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting β2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroids (LABA/ICS) combinations in patients at low and high risk for these events. In this review, small groups of experts critically evaluated mechanisms potentially responsible for the increased benefit of LABA/LAMA combinations over single LABDs or LABA/ICS in decreasing exacerbation. These included effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus production with impaired mucociliary clearance, and symptom severity. The data assembled and analyzed by each group were reviewed by all authors and combined into this manuscript. Available clinical results support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom severity may all contribute to decreasing exacerbations. While preclinical studies suggest LABAs and LAMAs have anti-inflammatory effects, such effects have not been demonstrated yet in patients with COPD.

Type: Article
Title: How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1164/rccm.201609-1794CI
Publisher version: http://dx.doi.org/10.1164/rccm.201609-1794CI
Language: English
Additional information: Originally published in the American Journal of Respiratory and Critical Care Medicine: [Beeh, KM; Burgel, PR; Franssen, FM; Lopez-Campos, JL; Loukides, S; Hurst, JR; Fležar, M; (2016) How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? American Journal of Respiratory and Critical Care Medicine (In press). DOI: 10.1164/rccm.201609-1794CI]. Copyright © 2016 by the American Thoracic Society The final publication is available at http://dx.doi.org/10.1164/rccm.201609-1794CI
Keywords: hyperinflation, inflammation, inhaled corticosteroid, mucus
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Respiratory Medicine
URI: http://discovery.ucl.ac.uk/id/eprint/1533027
Downloads since deposit
177Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item